219 related articles for article (PubMed ID: 12084878)
1. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
[TBL] [Abstract][Full Text] [Related]
2. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
Pachner AR; Warth JD; Pace A; Goelz S;
Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
[TBL] [Abstract][Full Text] [Related]
3. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
[TBL] [Abstract][Full Text] [Related]
4. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.
Vallittu AM; Salmi AA; Erälinna JP;
Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938
[TBL] [Abstract][Full Text] [Related]
5. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
6. BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.
Cakal B; Uygunoglu U; Saip S; Altintas A; Siva A; Badur S
J Immunoassay Immunochem; 2014; 35(4):398-411. PubMed ID: 24547871
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the relative bioavailability of different interferon beta preparations.
Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
[TBL] [Abstract][Full Text] [Related]
8. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
Deisenhammer F; Reindl M; Harvey J; Gasse T; Dilitz E; Berger T
Neurology; 1999 Apr; 52(6):1239-43. PubMed ID: 10214750
[TBL] [Abstract][Full Text] [Related]
10. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
11. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
12. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
13. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
14. MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.
Libertinova J; Meluzinova E; Matoska V; Zajac M; Kovarova I; Havrdova E; Horakova D; Tomek A; Marusic P; Bojar M
Brain Behav; 2017 Mar; 7(3):e00644. PubMed ID: 28293479
[TBL] [Abstract][Full Text] [Related]
15. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
16. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
[TBL] [Abstract][Full Text] [Related]
17. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
[TBL] [Abstract][Full Text] [Related]
18. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
19. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
20. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
Pachner A; Narayan K; Price N; Hurd M; Dail D
Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
